Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies
- 20 December 1990
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 37 (6) , 1089-1095
- https://doi.org/10.1016/0960-0760(90)90471-v
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Octreotide and Bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castrationEuropean Journal of Cancer and Clinical Oncology, 1990
- The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumorsBreast Cancer Research and Treatment, 1990
- Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated diseaseEuropean Journal of Cancer and Clinical Oncology, 1990
- Antiproliferative effects of suramin on androgen responsive tumour cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- Modulation of development of dietary fat-promoted (pre)neoplastic pancreatic lesions in bop-treated hamsters by (anti) hormonesEuropean Journal of Cancer and Clinical Oncology, 1990
- Phase I/II study of suramin in hormone resistant metastatic prostate cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Suramin: Pharmacokinetic monitoring, haematological and antitumor effects on rats bearing transplantable pancreatic tumorsEuropean Journal of Cancer and Clinical Oncology, 1990
- Remission of metastatic breast cancer after combined somatostatin and antiprolactin treatmentEuropean Journal of Cancer and Clinical Oncology, 1990
- Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatinBreast Cancer Research and Treatment, 1989
- Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancerBreast Cancer Research and Treatment, 1989